Navigation Links
Cell Transplantation reports a success in treating end-stage liver disease
Date:1/11/2011

Tampa, Fla. (Jan. 10, 2011) Transplanting their own (autologous) bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation (19:11). Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.

The study, carried out by a team of researchers in California and in Egypt, is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/.

According to the study's corresponding author, Dr. Mark A. Zern of the University of California Davis Medical Center, Sacramento, CA, patients with end-stage liver failure in Egypt have few treatment options but for transplantation. A shortage of donors and cost factors make that strategy unrealistic. Accordingly, this study sought to evaluate the safety and efficacy of transplanting autologous bone marrow-derived CD34+ stem cells in 48 patients, 36 of whom had chronic, end-stage hepatitis C-induced liver disease, and 12 with end-stage autoimmune liver disease.

"For all patients there was a statistically significant decrease in peritoneal cavity fluid, or 'ascites,'" said Dr. Zern. "There was also clinical and biochemical improvement in a large percentage of patients who received the transplantation."

The researchers reported that they obtained "reasonable numbers of CD34+ cells" that were then "amplified and partially differentiated into hepatocyte precursor cells."

"This enabled us to transplant as many as one billion of these cells per patient," explained Dr. Zern. "The finding of improvement in ascites in a significant number of patients is impressive and somewhat surprising, suggesting that cell transplantation might be clinically significant beyond the improvement in laboratory parameters."

They also report using granulocyte-colony stimulating factor (G-CSF) to "mobilizeCD34+ stem cells into peripheral circulation." The researchers anticipated that G-CSF would likely enhance a variety of circulating bone marrow-derived cells, producing growth factors which could "positively affect liver regeneration and perhaps have a positive effect on portal hypertension."

The team also reported that prior to transplantation, the cells were already beginning to develop a hepatocyte phenotype while in culture, suggesting that the cells may have acted as hepatocyte-like cells following engraftment. The researchers plan to compare routes of infusion to determine if peripheral infusion of transplanted cells will be adequate.

"The use of peripheral infusion would dramatically reduce both costs and risks for this cell transplantation, thus making the treatment an even more viable option in Egypt and throughout the world," concluded Dr. Zern.

"It would be very interesting to determine if the differentiation to hepatic precursors was a necessary step for this treatment," said Dr. Stephen Strom, a professor of pathology in the Department of Pathology at the University of Pittsburgh and section editor for Cell Transplantation. "Other research groups are now showing similar results with cells without any hepatic characteristics, including fractionated and unfractionated bone marrow and mesenchymal stem cells. Taken together, these data suggest that the positive effects these researchers find may be the result of paracrine effects from factors secreted by the donor cells. I look forward to reading about the outcome of future studies to determine the optimal route of administration and dose of these cells, as well as more long term follow up."


'/>"/>

Contact: David Eve
celltransplantation@gmail.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. Cord blood cell transplantation provides improvement for severely brain-injured child
2. Japanese researchers report on liver transplantation studies using animal and iPS cells
3. New cell transplantation journal launched
4. Ovarian transplantation restores fertility to old mice and also lengthens their lives
5. Coral transplantation the simple and cheap solution to reef restoration
6. Cell Transplantation reports consistent and successful islet isolations offer diabetes hope
7. Novel Parkinsons treatment strategy involves cell transplantation
8. Rare genetic disease successfully reversed using stem cell transplantation
9. Ovarian transplantation: First baby is born after a new technique
10. Ovarian transplantation: New technique gives greatly improved results in this delicate operation
11. REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... March 7, 2017   HireVue , the leading ... companies identify the best talent, faster, today announced the ... Officer (CSO) and Diana Kucer as Chief ... seasoned executive team poised to drive continued growth in ... a year of record bookings in 2017. ...
(Date:3/2/2017)... March 2, 2017 Summary This report ... and its partnering interests and activities since 2010. ... Read the full ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ...
(Date:3/2/2017)... March 2, 2017 Who risk to be ... Download the full report: https://www.reportbuyer.com/product/4313699/ WILL ... SENSOR FIELD? Fingerprint sensors using capacitive technology represent ... sensor vendor Idex forecasts an increase of 360% of ... and of the fingerprint sensor market between 2014 and ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... March 23, 2017  Agriculture technology company Cool Planet ... and note conversion to commercialize its Cool Terra and ... on developing products that are simultaneously profitable as well ... the last 18 months. This latest round of funding ... Partners. The company,s primary product, Cool ...
(Date:3/22/2017)... , March 22, 2017  Ascendis Pharma A/S ... innovative TransCon technology to address significant unmet medical ... for the full year ended December 31, 2016. ... for our company as we broadened our pipeline ... integrated rare disease company with an initial focus ...
(Date:3/22/2017)... , March 22, 2017 The ... states a research report by Transparency Market Research (TMR). ... Amgen Inc., and AbbVie Inc., accounted for a share ... prominent players in this market are focusing aggressively on ... portfolio, which is likely to lead to market consolidation ...
(Date:3/22/2017)... ... March 21, 2017 , ... Premier executive recruitment firm, Slone Partners, ... Firm by Hunt Scanlon Media. , Hunt Scanlon Media is one of ... referenced global news source in the human capital sector. , “It is a great ...
Breaking Biology Technology: